Quadrivalent influenza vaccine in the United States

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 596-599

  Suryadevara, Manika ^a   Domachowske, Joseph B ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Influenza virus; Quadrivalent influenza vaccine

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY;

ARTHRALGIA; CLINICAL EFFECTIVENESS; COUGHING; DECREASED APPETITE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; MYALGIA; NONHUMAN; NOTE; OROPHARYNX PAIN; OUTCOME ASSESSMENT; RHINOPHARYNGITIS; RHINORRHEA; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VACCINE PRODUCTION; VIRUS STRAIN; VOMITING; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; CHILD; FEMALE; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; MEDICINAL CHEMISTRY; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84898410381     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27115     Document Type: Note

References (18)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96; PMID:17544181; http://dx.doi.org/10.1016/j.vaccine.2007.03.046
2. Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari NA, Donauer S, Henderson D, Ambrose S, Kent D, et al.; New Vaccine Surveillance Network (NVSN). High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine 2010; 28:4913-9; PMID:20576536; http://dx.doi.org/10.1016/j.vaccine.2010.05.036
3. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014. MMWR Recomm Rep 2013; 62(RR-07):1-43; PMID:24048214
4. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175:59-68; PMID:2309452; http://dx.doi.org/10.1016/ 0042-6822(90)90186-U
5. Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008; 66:655-63; PMID:18504518; http://dx.doi.org/10.1007/s00239-008- 9119-z
6. Paul Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am J Public Health 2013; 103:e43-51; PMID:23327249; http://dx.doi.org/10.2105/AJPH.2012.301137
7. Chen JM, Guo YJ, Wu KY, Guo JF, Wang M, Dong J, Zhang Y, Li Z, Shu YL. Exploration of the emergence of the Victoria lineage of influenza B virus. Arch Virol 2007; 152:415-22; PMID:17075722; http://dx.doi.org/10.1007/s00705-006- 0852-6
8. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012; 8:81-8; PMID:22252006; http://dx.doi.org/10.4161/hv. 8.1.17623
9. Treanor J. Influenza vaccine - outmaneuvering antigenic shift and drift. N Engl J Med 2004; 350:218-20; PMID:14724300; http://dx.doi.org/10.1056/ NEJMp038238
10. Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013; 208:544-53; PMID:23847058; http://dx.doi.org/10.1093/infdis/jit263
11. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28:2149-56; PMID:20003926; http://dx.doi.org/10.1016/j.vaccine.2009.11.068
12. Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines 2012; 11:1293-303; PMID:23151111; http://dx.doi.org/10.1586/erv.12.108
13. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-8; PMID:22226861; http://dx.doi.org/10.1016/j.vaccine. 2011.12.098
14. Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011; 29:9391-7; PMID:21983154; http://dx.doi.org/10. 1016/j.vaccine.2011.09.109
15. Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012; 31:745-51; PMID:22466322; http://dx.doi.org/10.1097/INF.0b013e31825687b0
16. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >=18 years. BMC Infect Dis 2013; 13:343; PMID:23883186; http://dx.doi.org/10.1186/1471-2334-13-343
17. Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207:1878-87; PMID:23470848; http://dx.doi.org/10.1093/ infdis/jit091
18. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31:770-6; PMID:23228813; http://dx.doi.org/10.1016/j.vaccine.2012.11.074